Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 2/20 | 0.40 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31653661 | 0.91 | THRB (0.39) | MAPK3RORCMEN1KMT2ATHRB | |
| SCHEMBL31677853 | 0.89 | KDM4E (0.42) | RORCMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL31678805 | 0.88 | MAPK3 (0.39) | MAPK3RORCMEN1KMT2ATHRB | |
| SCHEMBL31677829 | 0.86 | MAPK14 (0.37) | — | |
| SCHEMBL31653789 | 0.84 | POLB (0.41) | MAPK3THRBMAPTRXFP1POLB | |
| SCHEMBL31677868 | 0.82 | RORC (0.40) | RORCMEN1KMT2AMAPTPOLB | |
| SCHEMBL31653817 | 0.82 | MAPT (0.40) | RORCMEN1KMT2AMAPTRXFP1 | |
| SCHEMBL31678000 | 0.81 | KMT2A (0.36) | MEN1KMT2AMAPTSMN1; SMN2LMNA | |
| SCHEMBL31677654 | 0.81 | KMT2A (0.43) | RORCMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL31653824 | 0.79 | KDM4E (0.46) | RORCMEN1KMT2AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270217-A1 | IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2025-08-28 | — | — | US | claimed |
| US-20250270217-A1 | IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2025-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270217-A1 | IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS | WRN, RECQL, BLM | MAPK3 2689/4885RORC 1053/4885MEN1 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.